HRTX logo

Heron Therapeutics (HRTX) Company Overview

Profile

Full Name:

Heron Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

August 26, 1987

Indexes:

Not included

Website:

http://www.herontx.com

Description:

Heron Therapeutics, Inc. is a commercial biotechnology company focused on improving the lives of patients by developing new methods of treating post-operative pain and cancer. Products SUSTOL and CINVANTI have been developed for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of chemotherapy, these two drugs have been approved and are already being marketed by the Company. HTX-011 for the treatment of post-operative pain is awaiting FDA approval. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Key Details

Price

$2.43

Market Cap

$369.54 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$144.28 M(+13.57% YoY)

Annual EPS

-

PE Ratio

-

Annual ROE

40.36%

Annual Debt To Equity

-5.28

Beta

1.69

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Feb 27, 2025

Recent annual earnings:

Feb 27, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jan 13, 2014

Analyst ratings

Recent major analysts updates

Feb 28, 25 Needham
Buy
Dec 4, 24 Needham
Buy
Nov 13, 24 Needham
Buy
Sep 25, 24 Needham
Buy
Aug 7, 24 Needham
Buy
Jun 13, 24 Rodman & Renshaw
Buy
May 16, 24 Needham
Buy
May 8, 24 Needham
Buy
Apr 23, 24 Capital One
Overweight
Apr 11, 24 Needham
Buy

Screeners with HRTX included

Growing Shares Outstanding
US stocks
Stocks with high beta
Most recommended stocks
Stocks below analysts price target
Healthcare sector
All stocks
Biotechnology industry
Small cap stocks
NASDAQ earnings calendar

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$2.43
HRTX price is $2.43

Price All-time High

$1270.00
HRTX price is currently -99.81% below its historical high of $1270.00

Price Analysts Target

$5.00
HRTX price is currently -51.41% lower than the consensus analysts' forecast

Price Most Recent Change

-4.72%
HRTX price was down -4.72% on Mar 6, 2025

Price YTD Change

+58.84%
HRTX price is up +58.84% since January 1st

Price 3-Year Change

-54.24%
HRTX price is down -54.24% over the past 3 years

Market cap

Market Cap

$369.54 M
HRTX market capitalization is $369.54 million

Market Cap 3-Year Change

-31.86%
HRTX market capitalization is down -31.86% over the past 3 years

Market Cap All-time High

$3.18 B
HRTX market capitalization is currently -88.38% below its historical high of $3.18 billion

Market Cap Sector Rank

63.37%
HRTX market capitalization is higher than 63.37% of companies in Healthcare sector

Technical

Beta

1.69
HRTX beta is 1.69

200-day SMA

$2.17
HRTX price is currently +11.82% above its 200-day simple moving average

14-day RSI

65.76
HRTX 14-day relative strength index is 65.76

30-day Relative Volume

1.90
HRTX 30-day relative volume is 1.90

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$144.28 M
HRTX annual revenue is $144.28 million

Annual Revenue Analysts Estimate

$158.17 M
HRTX annual revenue is currently -8.78% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+13.57%
HRTX annual revenue is up +13.57% year-on-year

Annual Revenue Sector Rank

61.25%
HRTX annual revenue is higher than 61.25% of companies in Healthcare sector

Profit

Annual Gross Profit

$105.64 M
HRTX annual gross profit is $105.64 million

Annual Gross Margin

73.21%
HRTX annual gross profit margin is 73.21%

Annual Operating Profit

-$11.53 M
HRTX annual operating income is -$11.53 million

Annual Operating Margin

-7.99%
HRTX annual operating profit margin is -7.99%

Annual Net Income

-$13.58 M
HRTX annual net profit is -$13.58 million

Annual Net Margin

-
HRTX annual net profit margin value is unknown

EPS

Annual EPS

-
HRTX annual earnings per share value is unknown

Annual EPS Analysts Estimate

-$0.03
HRTX annual earnings per share is currently equal to the consensus analysts' forecast

Annual EPS 1-Year Change

-
HRTX annual earnings per share 1-year change is unknown

Annual EPS Sector Rank

-
HRTX annual earnings per share is unknown

ROA & ROE

Annual ROA

-5.82%
HRTX annual return on assets is -5.82%

Annual ROE

40.36%
HRTX annual return on equity is 40.36%

EBIT & EBITDA

Annual EBIT

-$7.55 M
HRTX annual earnings before interest & taxes is -$7.55 million

Annual EBITDA

-$5.06 M
HRTX annual EBITDA is -$5.06 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
HRTX price to earnings ratio value is unknown

PE Ratio Sector Rank

-
HRTX price to earnings ratio is unknown

PB Ratio

PB Ratio

-10.98
HRTX price to book ratio is -10.98

PB Ratio Sector Rank

2.23%
HRTX price to book ratio is higher than 2.23% of companies in Healthcare sector

PS Ratio

PS Ratio

2.56
HRTX price to sales ratio is 2.56

PS Ratio Sector Rank

45.58%
HRTX price to sales ratio is higher than 45.58% of companies in Healthcare sector

Enterprise value

Enterprise Value

$521.51 M
HRTX enterprise value is $521.51 million

Enterprise Value Sector Rank

69.01%
HRTX enterprise value is higher than 69.01% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-103.15
HRTX EV/EBITDA is -103.15

EV/EBITDA Sector Rank

1.15%
HRTX EV/EBITDA is higher than 1.15% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

2.29
HRTX annual current ratio is 2.29

Annual Quick Ratio

1.70
HRTX annual quick ratio is 1.70

Leverage

Annual Debt To Equity

-5.28
HRTX annual debt to equity ratio is -5.28

Annual Interest Coverage Ratio

-1.25
HRTX annual interest coverage ratio is -1.25

Risk & Stability

Piotroski F-Score

3
HRTX piotroski f-score is 3

Altman Z-Score

-9.58
HRTX altman z-score is -9.58

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$233.15 M
HRTX annual total assets is $233.15 million

Annual Non Current Assets

$24.13 M
HRTX annual long term assets is $24.13 million

Annual Current Assets

$209.01 M
HRTX annual total current assets is $209.01 million

Annual Cash & Cash Equivalents

$25.80 M
HRTX annual cash & cash equivalents is $25.80 million

Equity

Annual Book Value

-$33.65 M
HRTX annual book value is -$33.65 million

Annual Working Capital

$117.56 M
HRTX annual working capital is $117.56 million

Liabilities

Annual Total Liabilities

$266.80 M
HRTX annual total liabilities is $266.80 million

Annual Total Long Term Liabilities

$175.34 M
HRTX annual total long term liabilities is $175.34 million

Annual Current Liabilities

$91.46 M
HRTX annual total current liabilities is $91.46 million

Annual Accounts Payable

$11.71 M
HRTX annual accounts payable is $11.71 million

Debt

Annual Total Debt

$177.76 M
HRTX annual total debt is $177.76 million

Annual Total Debt 1-Year Change

-1.04%
HRTX annual total debt is down -1.04% year-on-year

Annual Long Term Debt

$174.73 M
HRTX annual long term debt is $174.73 million

Annual Short Term Debt

-
HRTX annual short term debt value is unknown

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$155.81 M
HRTX annual total expenses is $155.81 million

Annual Operating Expenses

$117.17 M
HRTX annual total operating expenses is $117.17 million

Annual Cost Of Goods Sold

$38.65 M
HRTX annual cost of goods sold is $38.65 million

Annual SGA

$100.48 M
HRTX annual SGA is $100.48 million

Annual D&A

$2.49 M
HRTX annual depreciation & amortization is $2.49 million

Annual Interest Expense

$6.03 M
HRTX annual interest expense is $6.03 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$22.53 M
HRTX annual cash flow from operations is -$22.53 million

Annual CFO 1-Year Change

+61.68%
HRTX annual cash flow from operations is up +61.68% year-on-year

Annual CFI

$18.71 M
HRTX annual cash flow from investing activities is $18.71 million

Annual CFI 1-Year Change

+4%
HRTX annual cash flow from investing activities is up +4% year-on-year

Annual CFF

$940.00 K
HRTX annual cash flow from financing activities is $940.00 thousand

Annual CFF 1-Year Change

-98.26%
HRTX annual cash flow from financing activities is down -98.26% year-on-year

Free CashFlow

Annual FCF

-$24.23 M
HRTX annual free cash flow is -$24.23 million

Annual FCF 1-Year Change

+59.83%
HRTX annual free cash flow is up +59.83% year-on-year

CAPEX

Annual CAPEX

$1.71 M
HRTX annual capital expenditures is $1.71 million

Annual CAPEX 1-Year Change

+10.42%
HRTX annual capital expenditures is up +10.42% year-on-year

Institutional Ownership

Similar stocks

ZIMV logo
ZimVie (ZIMV)
NNOX logo
Nano-X Imaging (NNOX)
CMPX logo
Compass Therapeutics (CMPX)
GLUE logo
Monte Rosa Therapeutics (GLUE)
ALDX logo
Aldeyra Therapeutics (ALDX)
AURA logo
Aura Biosciences (AURA)
SMLR logo
Semler Scientific (SMLR)
CELC logo
Celcuity (CELC)
MXCT logo
MaxCyte (MXCT)

FAQ

  • What is the ticker symbol for Heron Therapeutics?
  • Does Heron Therapeutics pay dividends?
  • What sector is Heron Therapeutics in?
  • What industry is Heron Therapeutics in?
  • What country is Heron Therapeutics based in?
  • When did Heron Therapeutics go public?
  • Is Heron Therapeutics in the S&P 500?
  • Is Heron Therapeutics in the NASDAQ 100?
  • Is Heron Therapeutics in the Dow Jones?
  • When was Heron Therapeutics's last earnings report?
  • When does Heron Therapeutics report earnings?
  • Should I buy Heron Therapeutics stock now?

What is the ticker symbol for Heron Therapeutics?

The ticker symbol for Heron Therapeutics is NASDAQ:HRTX

Does Heron Therapeutics pay dividends?

No, Heron Therapeutics does not pay dividends

What sector is Heron Therapeutics in?

Heron Therapeutics is in the Healthcare sector

What industry is Heron Therapeutics in?

Heron Therapeutics is in the Biotechnology industry

What country is Heron Therapeutics based in?

Heron Therapeutics is headquartered in United States

When did Heron Therapeutics go public?

Heron Therapeutics's initial public offering (IPO) was on August 26, 1987

Is Heron Therapeutics in the S&P 500?

No, Heron Therapeutics is not included in the S&P 500 index

Is Heron Therapeutics in the NASDAQ 100?

No, Heron Therapeutics is not included in the NASDAQ 100 index

Is Heron Therapeutics in the Dow Jones?

No, Heron Therapeutics is not included in the Dow Jones index

When was Heron Therapeutics's last earnings report?

Heron Therapeutics's most recent earnings report was on Feb 27, 2025

When does Heron Therapeutics report earnings?

The date for Heron Therapeutics's next earnings report has not been announced yet

Should I buy Heron Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions